OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors

NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company*.

Alexandre Lebeaut has more than 25 years of a valuable experience and leadership both in innovation, research and development, from preclinical to post-marketing stage and with major achievements in particular in immunology, oncology, immuno-inflammation and infectious diseases. He has held various global positions, notably in the United States at Bluebird Bio, Sanofi, Novartis and Schering Plough Research Institute. Most recently, Alexandre Lebeaut served as Executive Vice-President R&D and Chief Scientific Officer at Ipsen in the US. He currently heads “I-ACT for Children” (Institute for Advanced Clinical Trials), an American non-profit organization based in Maryland which is dedicated to pediatric drug development.

Alexandre is a French and US citizen and is a Doctor of Medicine (University of Paris Diderot Paris VII) and a pediatrician (University of Paris Descartes).

« We are very pleased to welcome Alexandre who brings an extensive American and international experience and leadership in R&D strategic positions, and particularly in immunology. His recognized expertise is in match with the Company’s new phase of growth focused on advancing our preclinical and clinical diversified first-in-class portfolio in immuno-oncology and immunology & inflammation”, comments Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.

Alexandre Lebeaut added: « I am honored to be joining OSE’s Board and I thank the Directors for their confidence. Along with the management team, I will be happy to contribute to the Company’s growth in this critical phase of its transformation by further establishing OSE as a recognized leader in immunotherapy and by enlarging its global visibility”.

On proposal from the Nomination and Remuneration Committee, the Board of Directors unanimously co-opted Alexandre Lebeaut as an independent Director. This appointment will be subject to ratification at the next annual shareholders’ meeting.

* Replacing Alexis Peyroles who resigned as a Board member

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Immuno-Oncology first-in-class products

  • Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure.
    Other ongoing combination trials sponsored by cooperative clinical research groups in oncology:
      Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
      Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
      Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1.
  • OSE-279, anti-PD1 – advanced preclinical stage.
  • BiCKI®: bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target (for example: BiCKI®-IL7, preclinical stage) to increase anti-tumor efficacy.

Immunity & Inflammation first-in-class products

  • OSE-127/S95011 (humanized monoclonal antibody antagonist of IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; ongoing Phase 2 in ulcerative colitis (sponsor OSE) and ongoing Phase 2a in Sjögren’s syndrome (sponsor Servier).
  • FR104 (anti-CD28 monoclonal antibody): licensing partnership agreement with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsored by the Nantes University Hospital); US IND obtained by Veloxis Pharmaceuticals, Inc. for a clinical trial; Phase 2 planned in an autoimmune disease indication.
  • OSE-230 (ChemR23 agonist mAb): preclinical stage therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

CoVepiT: a prophylactic second-generation vaccine activating cytotoxic T lymphocytes against COVID-19, developed using optimized epitopes from SARS-CoV2 viral proteins, epitopes non impacted by multi-variants. Shows good tolerance and very good level of T cell immune response. Results from 6-month memory T cell responses expected Q1 2022.

For more information: https://ose-immuno.com/en/


Click and follow us on Twitter and Linkedln


OSE Immunotherapeutics Media  
Sylvie Détry
+33 153 198 757
U.S. Media: LifeSci Communications
Darren Opland, Ph.D.
+1 646 627 8387
Guillaume van Renterghem – LifeSci Advisors
+41 76 735 01 31
Investor Relations
Thomas Guillot
+33 607 380 431
French Media: FP2COM
Florence Portejoie
+33 607 768 283

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2021, including the annual financial report for the fiscal year 2020, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Primary Logo

Back to news